At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

In a phase III trial, pre-op MRI did not reduce locoregional recurrences or improve survival among women with early-stage ...

Is omission of the sentinel lymph node biopsy safe in early breast cancer in patients treated with breast conserving therapy ...

Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...

Greenwich LifeSciences (GLSI) announced an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of FLAMINGO-01. A ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Variance in incidence seen across cancer types, but consistently increased with later stage at initial diagnosis.

RT consisted of a conventionally fractionated regimen, with the delivery of a total dose of 60 Gy in 6 weeks, in a once-daily schedule of 2 Gy per fraction for a total of 30 fractions. Patients were ...

Patients with stage I or II hormone receptor-negative breast cancer do not benefit from preoperative breast MRI, according to ...

Primary disease recurrence after renal transplantation accounts for 7–8% of graft losses Disease recurrence after paediatric renal transplantation can be associated with a high or low risk of graft ...